Skip to main content
Log in

Experience with bisoprolol in long-QT1 and long-QT2 syndrome

  • MULTIMEDIA REPORT
  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Background

The protective effect of beta-blockers in patients with inherited Long-QT syndrome is well established. Recent reports have suggested that beta-blockers are not equally effective in Long-QT (LQT). Bisoprolol is an attractive candidate for use in LQT because of its cardioselective properties and favorable side-effect profile.

Methods

We performed a retrospective cohort study of 114 consecutive patients with gene-positive Long-QT syndrome type 1 (LQT1) or Long-QT syndrome type 2 (LQT2) treated with bisoprolol, nadolol or atenolol with a total of 580 person-years of follow-up. Electrocardiogram (ECG) parameters and cardiac events during follow-up were compared. In addition, exercise treadmill testing was performed in bisoprolol-treated patients.

Results

Fifty-nine patients were treated with bisoprolol, 39 with atenolol and 16 with nadolol. Overall, 59 % were females and 62 % had LQT1. Baseline heart rate and corrected QT (QTc) interval were similar between the groups. QTc shortening was observed in individuals on bisoprolol (ΔQTc −5 ± 31 ms; p = 0.049) and nadolol (ΔQTc −13 ± 16 ms; p = 0.02) but not on atenolol (ΔQTc +9 ± 24 ms; p = 0.16). Median follow-up was similar for bisoprolol and nadolol (3 years), but longer for atenolol (6 years; p = 0.03); one cardiac event occurred in the bisoprolol group (1.7 %) and two events occurred in the atenolol group (5.1 %; p = 0.45), whereas none occurred in nadolol-treated patients. Beta-blocker efficacy was not affected by the underlying genotype. The antiadrenergic effect of bisoprolol correlated with the reduction of peak heart rates at exercise testing.

Conclusions

Bisoprolol treatment results in QTc shortening in gene-positive LQT1 and LQT2 patients and is well tolerated during long-term administration. The equivalence of bisoprolol for protection from ventricular arrhythmia in LQT patients compared to established beta-blockers remains unknown. Further large-scale studies are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

BB:

Beta-blocker

Bpm:

Beats per minute

ECG:

Electrocardiogram

HR:

Heart rate

ICD:

Implantable cardioverter defibrillator

IQR:

Interquartile range

LQT:

Long-QT syndrome

LQT1:

Long-QT syndrome type 1

LQT2:

Long-QT syndrome type 2

N/A:

Not applicable

QTa:

Absolute QT interval

QTc:

Corrected QT interval

SCD:

Sudden cardiac death

SD:

Standard deviation

References

  1. Roden DM. Clinical practice. Long-QT syndrome. N Engl J Med. 2008;358(2):169–76.

    Article  CAS  PubMed  Google Scholar 

  2. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012;5(4):868–77.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Obeyesekere MN, Antzelevitch C, Krahn AD. Management of ventricular arrhythmias in suspected channelopathies. Circ Arrhythm Electrophysiol. 2015;8(1):221–31.

    Article  PubMed  Google Scholar 

  4. Goldenberg I, Bradley J, Moss A, McNitt S, Polonsky S, Robinson JL, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol. 2010;21(8):893–901.

    PubMed  PubMed Central  Google Scholar 

  5. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101(6):616–23.

    Article  CAS  PubMed  Google Scholar 

  6. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292(11):1341–4.

    Article  CAS  PubMed  Google Scholar 

  7. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation. 2009;119(2):215–21.

    Article  CAS  PubMed  Google Scholar 

  8. Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012;60(20):2092–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. 2014;64(13):1352–8.

    Article  CAS  PubMed  Google Scholar 

  10. Wellstein A, Palm D, Belz GG, Leopold G, Buhring KU, Pabst J. Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S41–5.

    CAS  PubMed  Google Scholar 

  11. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther. 1999;13(2):123–6.

    Article  CAS  PubMed  Google Scholar 

  12. Prichard, B. N. Bisoprolol: a new beta-adrenoceptor blocking drug. Eur Heart J. 1987, 8 Suppl M, 121-129.

  13. Postema PG, Wilde AA. The measurement of the QT interval. Curr Cardiol Rev. 2014;10(3):287–94.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wong JA, Gula LJ, Klein GJ, Yee R, Skanes AC, Krahn AD. Utility of treadmill testing in identification and genotype prediction in long-QT syndrome. Circ Arrhythm Electrophysiol. 2010;3(2):120–5.

    Article  PubMed  Google Scholar 

  15. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932–63.

    Article  PubMed  Google Scholar 

  16. Bennett MT, Gula LJ, Klein GJ, Skanes AC, Yee R, Leong-Sit P, et al. Effect of beta-blockers on QT dynamics in the long QT syndrome: measuring the benefit. Europace. 2014;16(12):1847–51.

    Article  PubMed  Google Scholar 

  17. Viitasalo M, Oikarinen L, Swan H, Vaananen H, Jarvenpaa J, Hietanen H, et al. Effects of beta-blocker therapy on ventricular repolarization documented by 24-h electrocardiography in patients with type 1 long-QT syndrome. J Am Coll Cardiol. 2006;48(4):747–53.

    Article  CAS  PubMed  Google Scholar 

  18. Wilde AA, Ackerman MJ. Beta-blockers in the treatment of congenital long QT syndrome: is one beta-blocker superior to another? J Am Coll Cardiol. 2014;64(13):1359–61.

    Article  PubMed  Google Scholar 

  19. Chatrath R, Bell CM, Ackerman MJ. Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome. Pediatr Cardiol. 2004;25(5):459–65.

    Article  CAS  PubMed  Google Scholar 

  20. Moltedo JM, Kim JJ, Friedman RA, Kertesz NJ, Cannon BC. Use of a cardioselective beta-blocker for pediatric patients with prolonged QT syndrome. Pediatr Cardiol. 2011;32(1):63–6.

    Article  PubMed  Google Scholar 

  21. Fazio G, Vernuccio F, Lo Re G, Grutta G, Mongiovi M. Role of bisoprolol in patients with long QT syndrome. Ann Noninvasive Electrocardiol. 2013;18(5):467–70.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Santabhanu Chakrabarti.

Ethics declarations

The study was approved by the local ethics and review board of each participating center.

Funding

None

Conflict of interest

The authors declare that they have no conflict of interest

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Figure 1

Shown are the resting heart rates for LQTS-1 (A) and LQTS-2 (B) prior to beta-blocker initiation and on stable beta-blocker dose. Data are presented as mean ± SD. (TIFF 70 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steinberg, C., Padfield, G.J., Al-Sabeq, B. et al. Experience with bisoprolol in long-QT1 and long-QT2 syndrome. J Interv Card Electrophysiol 47, 163–170 (2016). https://doi.org/10.1007/s10840-016-0161-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-016-0161-2

Keywords

Navigation